Publikationen in Zusammenarbeit mit Forschern von German Cancer Research Center (11)

2023

  1. Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells

    Molecular Therapy - Nucleic Acids, Vol. 32, pp. 322-339

2022

  1. Autophagy in Hematological Malignancies

    Cancers, Vol. 14, Núm. 20

  2. Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study

    Blood Cancer Journal

2021

  1. Polymorphisms within the TNFSF4 and mapkapk2 loci influence the risk of developing invasive aspergillosis: A two-stage case control study in the context of the aspbiomics consortium

    Journal of Fungi, Vol. 7, Núm. 1, pp. 1-17

2020

  1. Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium

    Blood Cancer Journal, Vol. 10, Núm. 7

2016

  1. Redefining cancer immunotherapy—optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27–30, 2015, Ljubljana, Slovenia

    Cancer Immunology, Immunotherapy, Vol. 65, Núm. 7, pp. 875-883

  2. The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells

    Oncotarget, Vol. 7, Núm. 16, pp. 21875-21886

2012

  1. Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward

    Journal of Immunotoxicology, Vol. 9, Núm. 3, pp. 231-235

  2. From cell regulation to patient survival: 2nd Cancer immunotherapy and immunomonitoring (CITIM) meeting, Budapest, 2-5 May 2011

    Cancer Immunology, Immunotherapy

2009

  1. Efficient recovery of HLA class i expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: Implications for cancer immunotherapy

    Scandinavian Journal of Immunology, Vol. 70, Núm. 2, pp. 125-135

1980

  1. Foreign H-2-like molecules on a murine tumor (MCG4): Target antigens for alloreactive cytolytic T lymphocytes (CTL) and restricting elements for virus-specific CTL

    Transplantation Proceedings, Vol. 12, Núm. 1, pp. 32-37